By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer Surgery has been the primary treatment for early stage non-small cell lung cancer (NSCLC). Unfortunately, many people have seen their cancer come back after surgery. Now researchers [...]
By Andrew Ciupek, PhD, Senior Manager, Clinical Research, GO2 for Lung CancerA number of studies presented at the American Society of Clinical Oncology’s (ASCO) Annual Meeting related to the treatment of non-small cell lung cancer (NSCLC) with an EGFR mutation.Tagrisso [...]
On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of [...]
By Andrew Ciupek, Ph.D., Manager, Clinical Research, GO2 for Lung Cancer Approximately 30% of Non-Small Cell Lung Cancers (NSCLC) have an EGFR mutation. For these patients EGFR targeted therapy has greatly increased survival. Tagrisso (osimertinib) has become the drug [...]
On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for the adjuvant treatment of stage IB-IIIA non-small cell lung cancer (NSCLC) that has been surgically removed, when the cancer has a change in EGFR. The [...]
We fight lung cancer together. That’s a lesson we’ve learned and put into action. Amy C. Moore, PhD, our Director of Science & Research, recently published an article in the International Association for the Study of Lung Cancer online [...]
Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based [...]
Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The [...]
By Dr. Robert Smyth, MB, MSc As a trainee in pulmonary medicine, lung cancer has long interested me. It is the leading cancer killer worldwide and estimated to be responsible for 1.6 million deaths, about a fifth of all [...]
Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q [...]